OCA
Octagon Capital Advisors Portfolio holdings
AUM
$456M
This Quarter Return
-6.63%
1 Year Return
+48.55%
3 Year Return
+560.4%
5 Year Return
–
10 Year Return
–
AUM
$508M
AUM Growth
+$508M
(-14%)
Cap. Flow
-$65.3M
Cap. Flow
% of AUM
-12.85%
Top 10 Holdings %
Top 10 Hldgs %
56.68%
Holding
38
New
7
Increased
4
Reduced
10
Closed
4
Top Buys
Top Sells
| 1 |
KLRS
Kalaris Therapeutics, Inc. Common Stock
KLRS
|
$86.2M |
| 2 |
Insmed
INSM
|
$22.9M |
| 3 |
VRNA
Verona Pharma
VRNA
|
$22.5M |
| 4 |
Apellis Pharmaceuticals
APLS
|
$20M |
| 5 |
Dyne Therapeutics
DYN
|
$15.7M |
Sector Composition
| 1 | Healthcare | 90.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Nuvation Bio Inc. Redeemable warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50
NUVB.WS
$68M
| $48.1M | 9.31% | 27,330,800 +27,018,464 | +8,650% | +$47.6M |
|
|
2
Apellis Pharmaceuticals
APLS
$3.48B
| $45.8M | 8.86% | 2,094,000 -912,980 | -30% | -$20M |
|
3
Dianthus Therapeutics
DNTH
$759M
| $42.5M | 8.22% | 2,341,667 +231,500 | +11% | +$4.2M |
|
4
ArriVent BioPharma
AVBP
$776M
| $38.1M | 7.37% | 2,059,387 | – | – |
|
5
Trevi Therapeutics
TRVI
$883M
| $20.9M | 4.04% | +3,322,000 | New | +$20.9M |
|
|
CNTA
6
Centessa Pharmaceuticals
CNTA
$2.25B
| $20.5M | 3.97% | 1,425,000 -568,052 | -29% | -$8.17M |
|
7
Gossamer Bio
GOSS
$562M
| $20.2M | 3.91% | 18,350,000 | – | – |
|
8
Ocular Therapeutix
OCUL
$2.12B
| $17.8M | 3.44% | 2,425,000 | – | – |
|
9
MindMed
MNMD
$676M
| $17.7M | 3.42% | 3,018,000 | – | – |
|
10
Cogent Biosciences
COGT
$1.69B
| $16.6M | 3.2% | 2,763,000 | – | – |
|
11
KalVista Pharmaceuticals
KALV
$678M
| $15.8M | 3.06% | 1,370,000 | – | – |
|
12
Taysha Gene Therapies
TSHA
$797M
| $14.9M | 2.88% | 10,700,000 +250,000 | +2% | +$348K |
|
|
13
Nuvation Bio
NUVB
$1.02B
| $13.9M | 2.69% | 7,900,000 -1,302,907 | -14% | -$2.29M |
|
|
VRNA
14
Verona Pharma
VRNA
$9.16B
| $13.8M | 2.67% | 217,264 -354,000 | -62% | -$22.5M |
|
15
Tourmaline Bio
TRML
$601M
| $13.8M | 2.66% | +905,000 | New | +$13.8M |
|
16
Merus
MRUS
$4.98B
| $13M | 2.51% | 308,000 | – | – |
|
17
Pharvaris
PHVS
$1.39B
| $12.1M | 2.34% | 769,815 -8,185 | -1% | -$129K |
|
18
MoonLake Immunotherapeutics
MLTX
$3.54B
| $11.6M | 2.24% | +296,000 | New | +$11.6M |
|
19
Syndax Pharmaceuticals
SNDX
$1.41B
| $11.1M | 2.15% | 904,000 | – | – |
|
|
ATYR
20
aTyr Pharma
ATYR
$527M
| $10.7M | 2.08% | 3,552,000 +2,652,000 | +295% | +$8.01M |
|
21
Scholar Rock
SRRK
$3.14B
| $10.6M | 2.05% | 329,000 -159,000 | -33% | -$5.11M |
|
22
Verastem
VSTM
$569M
| $10.4M | 2.01% | +1,720,000 | New | +$10.4M |
|
|
RGLS
23
DELISTED
Regulus Therapeutics
RGLS
| $8.11M | 1.57% | 4,637,076 -211,726 | -4% | -$371K |
|
24
ARS Pharmaceuticals
SPRY
$1.15B
| $7.86M | 1.52% | +625,000 | New | +$7.86M |
|
|
ABVX
25
Abivax
ABVX
$6.12B
| $7.69M | 1.49% | +1,230,000 | New | +$7.69M |
|